Современное состояние разработки вакцин нового поколения против болезни, вызванной вирусом Эбола

СтатьяПРОБ ОСОБ ОПАС ИНФ. 2015; № 3: 104–109. DOI:10.21055/0370-1069-2015-3-104-109

Сизикова Т.Е.^[1]

Лебедев В.Н.^[1]

Борисевич С.В.^[1]

Кутаев Д.А.^[1]

Борисевич И.В.^[2]

^[1]48 Центральный НИИ Министерства обороны

^[2]Научный центр экспертизы средств медицинского применения (Москва)

вирус Эбола

филовирусы

специфическая профилактика

векторные рекомбинантные вакцины

ДНК-вакцины

вирусподобные частицы

РНК-репликоны

аденовирус

вирус везикулярного стоматита

Ebola virus

hemorrhagic fever

filoviruses

specific prophylaxis

vector recombinant vaccines

DNA-vaccines

virus-like particles

RNA-replicons

adenovirus

vesicular stomatitis virus

Adenoviridae

Filoviridae

Болезнь

Вакцины

Везикулярный стоматит

Вирусы папилломы человека

Время

Гликопротеины

Иммунизация

Карповые

Лихорадка

Макаки

Мыши

Нуклеопротеины

Разработка вакцин

Человек

Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., Paragas J., Hogan R.J., Schmaljohn C. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J. Virol. 2007; 81(4):1821-37.

Emond R.T. Viral hemorrhagic fevers. J. Infect. 1986; 13:103-6.

Feldmann H., Geisbert T.W. Ebola hemorrhagic fever. Lancet. 2011; 377:849-62.

Feldmann H., Jones S., Klenk H.D., Schnittler H.J. Ebola virus: From discovery to vaccine. Nat. Rev. Immunol. 2003; 3:677-85.

Geisbert T.W., Daddario-DiCaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., Stroher U., Fritz E.A., Hensley L.E., Jones S.M., Feldmann H. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008; 26:6894-900.

Geisbert T.W., Daddario-DiCaprio K.M., Lewis M.G., Geisbert J.B., Grolla A., Leung A., Paragas J., Matthias L., Smith M.A., Jones S.M., Hensley L.E., Feldmann H., Jahrling P.B. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4(11):1-9.

Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J.N., Geisbert J.B., Leung A., Feldmann F., Hensley L.E., Feldmann H., Jones S.M. Recombinant vesicular stomatitis virus vector mediaters postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 2008; 82(11):5664-8.

Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 2011; 204(3):1075-81.

Geisbert T.W., Geisbert J.B., Leung A., Daddario-DiCaprio K.M., Hensley L.E., Grolla A., Feldmann H. Single-Injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 2009; 83(14):7296-304.

Kiley M.P., Bowen E.T., Eddy G.A., Isaacson M., Johnson K.M., McCormick J.B., Murphy F.A., Pattyn S.R., Peters D., Prozesky O.W., Regnery R.L., Simpson D.I.H., Slenczka W., Sureau P. van der Groen G., Webb P.A., Wulff H. Filoviridae: A taxonomic home for Marburg and Ebola viruses? Intervirology. 1982; 18:24-32.

Kobinger G.P., Croyle M., Feldmann H. Ebola and Marburg. Vaccines for Biodefense and Emerging and Neglected Diseases. London (UK): Academic Press; 2009. P. 25-37.

Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., Jones S., Wilson J.M. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. J. Virol. 2006; 346:394-401.

Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S., Smith L.A., Smith J.F. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice Vaccine. 2006; 24:6886-92.

Lesley C.D., Schmaljohn C.S. DNA vaccines for biodefense. Expert Rev. Vaccines. 2009; 8:739-54.

Lundstrom K. Alphavirus vectors for vaccine production and gene therapy. Expert Rev. Vaccines. 2003; 2:447-59.

MDPI Viruses [Internet]. Special Issue “Advances in Filovirus Research 2012” [cited 23 March 2015]. Available from: http://www.mdpi.com/journal/viruses/special_issues/Filovirus.http://www.mdpi.com/journal/viruses/special_issues/Filovirus

Mire C.E., Geisbert J.B., Marzi A., Agans K.N., Feldmann H., Geisbert T.W. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl. Trop. Dis. 2013; 7(12):1-11.

Nabel C., Yang Z., Sulliva N., Sanches A. Development of a preventive vaccine for filovirus infection in primates. Patent US 8.124 592 B2 2012.

Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003; 11:438-44.

Potential use of live viral and bacterial vectors for vaccines. WHO meeting, Geneva, 19-22 June, 1989. Vaccine. 1990; 8(5):425-37.

Pushko P., Geisbert J., Parker M., Jahrling P.B., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against lnfection with Lassa and Ebola viruses. J. Virol. 2001; 75:11677-85.

Radoshitzky S.R., Kuhn J.H., de Kok-Mercado F., Jahrling P.B., Bavari S. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin. Drug Discov. 2012; 7(7):613-32.

Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002; 12:279-96.

Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola Viruses. Fields virology. Philadelphia, PA, USA: Lippincott Williams and Wilkins; 2007. P. 1279-304.

Seregin A.V., Yun N.E., Poussard A.L., Peng B.-H., Smith J.F., Smith J.N., Milagros S., Paessler S. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine. 2010; 28:4713-8.

Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., Custers J.H.H.V., Popernack P.M., Yang Z.Y., Pau M.G., Roederer M., Koup R.A., Goudsmit J., Jahrling P.B., Nabel G.J. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Medicine. 2006; 3(6):865-73.

Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H., Dong J.Y., Pratt W.D. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. J. Clin. Vaccine Immunol. 2008;15(3):460-7.

Wang D., Raja N.U., Trubey C.M., Juompan L.Y., Luo M., Woraratanadharm J., Deitz S.B., Yu.H., Swain B.M., Moore K.M., Pratt W.D., Hart M.K., Dong J.Y. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 2006; 80(6):2738-46.

Warfield K.L., Bosio C.M., Welcher B.C. Ebola virus-like particles protect from lethal Ebola virus infection. J. Immunol. 2005; 175:1184-91.

Warfield K.L., Javad M.A. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis. 2011; 204(3):1053-59.

Warfield K.L., Swenson D.L, Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007; 196(2):430-7.

Warfield K.L., Swenson G.G., Demmin G., Bavari S. Filovirus-like particle as vaccines and discovery tools. Expert Rev. Vaccines. 2005; 4:429-40.

Язык текста: Русский

ISSN: 0370-1069